Announcements Trials
Browse Landscape

Phase

Phase 2 75Phase 3 17Phase 2/3 7Phase NA 6Phase 4 6Phase 1/2 5Phase 1 4

Status

Completed 253Terminated 62Active not recruiting 41Recruiting 35Withdrawn 20Unknown 17Not yet recruiting 4Suspended 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Breast 2Plasma cell 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Multiple Myeloma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Carboplatin × Clear all
NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Washington University School of Medicine

Phase 1 Not yet recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
90 enrolled
BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
762 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
350 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡